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Abstract 
The Plasmodium falciparum parasite’s ability to adapt to environmental pressures, such 
as the human immune system and antimalarial drugs, makes malaria an enduring burden 
to public health. Understanding the genetic basis of these adaptations is critical to 
intervening successfully against malaria. To that end, we created a high-density 
genotyping array that assays over 17,000 single nucleotide polymorphisms (~1 SNP/kb), 
and applied it to 57 culture-adapted parasites from three continents. We characterized 
genome-wide genetic diversity within and between populations and identified numerous 
loci with signals of natural selection, suggesting their role in recent adaptation. In 
addition, we performed a genome-wide association study (GWAS), searching for loci 
correlated with resistance to thirteen antimalarials; we detected both known and novel 
resistance loci, including a new halofantrine resistance locus, PF10_0355. Through 
functional testing we demonstrated that PF10_0355 overexpression decreases sensitivity 
to halofantrine, mefloquine and lumefantrine but not to structurally unrelated 
antimalarials, and that increased gene copy number mediates resistance. Our GWAS and 
follow-on functional validation demonstrate the potential of genome-wide studies to 
elucidate functionally important loci in the malaria parasite genome.  
   3 
Author Summary 
Malaria infection with the human pathogen, Plasmodium falciparum, results in almost a 
million deaths each year, mostly in African children. Efforts to eliminate malaria are 
underway, but the parasite is adept at eluding both the human immune response and 
antimalarial treatments.  Thus, it is important to understand how the parasite becomes 
resistant to drugs and to develop strategies to overcome resistance mechanisms.  Toward 
this end, we used population genetic strategies to identify genetic loci that contribute to 
parasite adaptation and to identify candidate genes involved in drug resistance.  We 
examined over 17,000 genetic variants across the parasite genome in over 50 strains in 
which we also measured responses to many known antimalarial compounds.  We found a 
number of genetic loci showing signs of recent natural selection and a number of loci 
potentially involved in modulating the parasite’s response to drugs. We further 
demonstrated that one of the novel candidate genes (PF10_0355) modulates resistance to 
the antimalarial compounds halofantrine, mefloquine and lumefantrine. Overall, this 
study confirms that we can use genome-wide approaches to identify clinically relevant 
genes and demonstrates through functional testing that at least one of these candidate 
genes is indeed involved in antimalarial drug resistance.    4 
Introduction 
Plasmodium falciparum malaria is a major public health challenge that contributes 
significantly to global morbidity and mortality. Efforts to control and eliminate malaria 
combine antimalarial drugs, bed nets and indoor residual spraying, with vaccine 
development a longer-term goal. Genetic variation in the parasite population threatens to 
undermine these efforts, as the parasite evolves rapidly to evade host immune systems, 
drugs and vaccines. Studying genetic variation in parasite populations will expand our 
understanding of basic parasite biology and its ability to adapt, and will allow us to track 
parasites as they respond to intervention efforts. Such understanding is increasingly 
important as countries move towards reducing disease burden and the ultimate 
elimination of malaria. 
Given the potential impact of rapid evolution of P. falciparum in response to control and 
eradication strategies, discovery and characterization of P. falciparum genetic diversity 
has accelerated in recent years. Since the first malaria genome was sequenced in 2002 
[1], over 60,000 unique SNPs have been identified by concerted sequencing efforts [2-4], 
and several genomic tiling arrays [5-9] and low-density SNP arrays [10,11] have been 
developed to query this genetic variation. Recently the first malaria GWAS was 
published [11], in which 189 drug-phenotyped parasites from Asia, Africa and the 
Americas were genotyped using a low-density array (3,257 SNPs); that study identified 
loci under positive selection and found several novel drug resistance candidates.   5 
For our study, we adopted two strategies for identifying genes involved in the malaria 
parasite’s adaptive response: searching for signals of recent or ongoing natural selection, 
and searching for loci associated with one important clinical adaptation—resistance to 
antimalarial drugs. To make these searches possible, we began by sequencing 9 
geographically diverse strains of P. falciparum to identify novel variation, thereby 
doubling the number of publicly available SNPs to 111,536 (all accessible at 
plasmodb.org), and used these SNPs to develop a high-density genotyping array assaying 
17,582 validated markers. After characterizing linkage disequilibrium and population 
structure in our samples, we used the arrays to search for evidence of both ongoing 
balancing selection and recent positive selection, and to carry out a GWAS that sought 
loci associated with resistance to thirteen antimalarial agents. We then followed up one of 
the novel loci associated with drug resistance in order to verify that variation there was 
biologically involved in modulating drug response.  
Results 
Genetic Diversity 
We identified global population structure among malaria parasites using principal 
components analysis (PCA) of 57 genotyped culture-adapted parasite samples (Figure 
1A, Table S1, Figure S1). African, American and Asian samples form three distinct 
clusters, reflecting the likely independent introduction of P. falciparum from Africa into 
Asia and the Americas.  There was little evidence for structure within Africa, suggesting 
high gene flow throughout the region (Figure S1). Asian and American parasites however 
both show substantial internal structure.   6 
There are also dramatic differences in linkage disequilibrium (LD) between populations, 
with substantial LD extending less than 1 kb in Senegal, 10 kb in Thailand, and 100 kb in 
Brazil (Figure S2).  These observations are consistent with previous findings, which 
showed that LD decays more rapidly in Africa, due either to founder effects in other 
continents [12] or to elevated outcrossing frequencies in Africa [12,13], where higher 
transmission intensity leads to a greater likelihood of sexual outcrossing rather than 
selfing within the mid-gut of vector mosquitoes.   
The short LD in malaria, driven by high levels of recombination, means that a high 
density of markers is required to identify candidate loci in association studies, since 
causal variants not on the array can seldom be tagged by neighboring alleles (Table S2).  
On the other hand, short LD can aid in fine-mapping candidate associations and greatly 
accelerates the search for causal genes.  Short LD also aids in identifying genomic 
regions under recent positive selection with recombination-based methods, since the 
increased LD in selected regions should stand out against the short-LD background. 
Detecting Signals of Natural Selection 
We expect that many parasite proteins that interact with the host immune system will be 
under balancing selection, because they will be under selective pressure to maintain high 
levels of diversity. Indeed, previous studies have shown that regions of the P. falciparum 
genome that are highly polymorphic and appear to be under balancing selection encode 
antigens that are recognized by the human immune system [4]. We examined evidence 
for balancing selection in our data by searching for regions with high nucleotide diversity 
(as measured by SNP π) and low population divergence (as measured by FST) (Figure   7 
1B). When we examined the loci lying in this region of the graph (Figure S3), we found a 
number of known antigens and vaccine candidates. Loci in the same region with 
unknown function are thus potential novel antigens that trigger human immune response 
to malaria, and may prove useful as biomarkers or as candidate vaccine molecules.  
We carried out a similar search for loci under positive selection by identifying regions 
with both low nucleotide diversity within Senegal and Thailand and high population 
divergence between the two populations (Figure 1B). We observed throughout the 
genome that nucleotide diversity was lower for nonsynonymous SNPs than for intergenic 
SNPs (Figure S4), a characteristic result of widespread purifying selection. At the same 
time, nonsynonymous SNPs exhibited significantly greater divergence than intergenic 
SNPs in all pairwise population comparisons, suggesting the effect of positive selection 
in local P. falciparum populations. Nonsynonymous SNPs with low diversity within a 
population and high divergence between the two populations studied may represent 
polymorphisms responsible for adaptive evolution.  
We also carried out a genome-wide scan for recent positive selection using the long-
range haplotype (LRH) test [14], which identifies common variants that have recently 
spread to high prevalence using recombination as a clock.  Approximately 15 genes were 
identified as having undergone recent positive selection by this approach, including 
known drug resistance loci (pfcrt and dhfr) as well as multiple members of the acyl-CoA 
synthetase (ACS) and ubiquitin protein ligase families (Figure S5 and S6); these latter 
genes also exhibit high divergence between Senegal and Thailand (Figure 1B), evidence 
for selection that is recent and population-specific. Taken as a group, the genes identified   8 
by the LRH test show a significant enrichment for higher than average population 
divergence (as measured by FST, Mann-Whitney U=1583, P=0.0071). All of these loci 
(Table S3, Dataset S1), which include genes in the folate metabolism, lipid biosynthesis 
and ubiquitin pathways, should be viewed as candidates for functional follow-up and 
further characterization. 
Genome-wide Associations with Drug Resistance 
In order to directly assess the genetic basis for one important response to antimalarial 
intervention, we carried out a GWAS to identify loci associated with drug resistance in 
parasites.  This same approach can potentially be applied to many other clinically 
relevant malaria phenotypes, e.g. host response, invasion, and gametocyte formation. Our 
first step was to measure drug resistance (IC50 values) to 13 antimalarial drugs 
(amodiaquine, artemether, artesunate, artemisinin, atovaquone, chloroquine, 
dihydroartemisinin, halofuginone, halofantrine, lumefantrine, mefloquine, piperaquine 
and quinine) in 50 culture-adapted parasites using a high-throughput assay (Tables S4 
and S5, Text S1, Dataset S1). 
We performed the genome-wide association analysis using two statistical tests: efficient 
mixed-model association (EMMA) and a haplotype likelihood ratio (HLR) test (Figures 
S7-S10, Methods).  EMMA identifies quantitative trait associations in individuals with 
complex population structure and hidden relatedness; it has previously been shown to 
outperform both PCA-based and λGC-based correction approaches in highly inbred and 
structured mouse, maize, and Arabidopsis populations [15].  EMMA is particularly 
applicable for small and structured sample sets: one of its first applications was in a study   9 
of 24 diploid mouse strains [15], essentially the same sample size as in our study (50 
haploid strains). The HLR test is a multi-marker test designed to detect the association of 
a single haplotype with a phenotype, and is particularly powerful when the associated 
haplotype experienced recent strong selection (and is therefore long) and occurs on a 
low-LD background [16]; it is therefore particularly appropriate for this study.  We 
addressed the effect of population structure in the HLR test using population-specific 
permutation (Methods).  When used together, these two complementary approaches 
provide a highly sensitive screen for association signals within the P. falciparum genome. 
The well-characterized chloroquine resistance locus, pfcrt, served as a positive control for 
our GWAS methods (Figure 2A and 2C, Table S2), an important test given our small 
sample size and the limited LD present in P. falciparum. As expected, we found evidence 
for association with resistance to chloroquine using both tests, consistent with previous 
studies [11]; EMMA yielded evidence for association with genome-wide signficance, 
while the signal from the HLR test fell just short of genome-wide significance (Figure 
2C).  
Applying the same tests to the other drug phenotypes, we detected numerous novel loci 
showing significant associations with drug resistance (Figure 2A and 2D, Table 1). 
Quantile-quantile plots for each test demonstrate that we were able to effectively control 
for population structure (Figure 2B). Despite our small sample size and the low LD in P. 
falciparum, in total eleven loci achieved genome-wide significance for association with 
resistance to five different drugs: amodiaquine, artemisinin, atovaquone, chloroquine and 
halofantrine. In most cases, the short extent of LD allowed localization to individual   10 
genes. Among the loci identified were various transporters and membrane proteins, as 
well as five conserved genes with unknown function (Table 1, Dataset S1). 
Functional Validation of a Novel Resistance Candidate 
Demonstrating that a signal of association actually reflects a causal molecular process 
requires functional testing and validation of the candidate locus, both because of concerns 
about power and reproducibility of genetic association tests, and because even a robust 
statistical correlation need not imply biological causation.  To confirm the ability of 
GWAS to identify functionally relevant candidates, we investigated one of our 
association findings, PF10_0355, in greater depth. This gene contains multiple SNPs 
associated with halofantrine resistance (Figure 2D), and encodes a putative erythrocyte 
membrane protein (PlasmoDB.org) characterized by high genetic diversity.  
We set out to determine the role of PF10_0355 in halofantrine resistance by transfecting 
halofantrine-sensitive Dd2 parasites with episomal plasmids containing the PF10_0355 
gene from a halofantrine-resistant parasite (SenP08.04), a technique that is used routinely 
for stable transgene expression [17]. Two independent transfectants overexpressing the 
PF10_0355 gene from SenP08.04 both showed reduced susceptibility to halofantrine 
when compared with the Dd2 parent or a transfection control (Figure 3A), suggesting that 
this gene is indeed involved in modulating parasite drug response. 
Two independent transfectants overexpressing the endogenous PF10_0355 gene from 
halofantrine-sensitive Dd2 also showed reduced susceptibility to halofantrine (Figure 
3A), however, pointing to a role of overexpression in the observed resistance. Because   11 
PF10_0355 is annotated as a putative erythrocyte membrane protein and belongs to the 
merozoite surface protein 3/6 family, we tested the hypothesis that the observed effect 
was the by-product of a growth or invasion-related process, rather than resistance due to a 
direct interaction with the antimalarial itself. To that end, we expanded our drug testing in 
the transfectant lines to include other antimalarials, some structurally related and some 
unrelated to halofantrine.  
Overexpression of PF10_0355 from either the Dd2 or the SenP08.04 parent caused 
increased resistance to the structurally related antimalarials mefloquine and lumefantrine 
(Figure 3B and 3C), but had no effect on parasite susceptibility to the structurally 
unrelated antimalarials chloroquine, artemisinin or atovaquone (Figure 3D and 3E). 
Indeed, we found evidence of cross-resistance between halofantrine and both mefloquine 
and lumefantrine (Figure 4). We also observed cross-resistance between halofantrine and 
artemisinin, which is expected as cross-resistance between aminoquinolines and 
artemisinin compounds has been previously demonstrated [11,18] and resistance to all 
these drugs has been shown to be mediated by changes in pfmdr1 copy number [19,20].  
Overexpression of PF10_0355, however, alters parasite susceptibility to the 
aminoquinolines but not to artemisinin, suggesting that this effect is specific for that set 
of structurally related compounds and distinct from the effect of pfmdr1, which seems to 
exert a global effect of resistance to unrelated compounds (i.e. both aminoquinolines and 
artemisinins). Using the Dd2 parasite line, which has amplified pfmdr1 copy number, as a 
background for PF10_0355 overexpression allowed us to distinguish between cross-
resistance to a structurally related class of compounds (mediated by PF10_0355 
overexpression) and pan-resistance to multiple classes of drugs.   12 
Given that overexpression of the PF10_0355 gene both from a halofantrine-resistant and 
from a sensitive parasite conferred resistance to halofantrine-related drugs, we 
investigated whether gene amplification might be driving the observed resistance, as it 
often does for antimalarial drugs [21-26]. We quantified PF10_0355 copy number in our 
transfectants and found that the transfectant with the highest IC50 for all three drugs 
(Dd2+P08B) also had the highest PF10_0355 copy number, as measured by quantitative 
PCR (qPCR) (Figure 5A). Furthermore, when we examined the PF10_0355 gene on our 
SNP array, we detected a substantial increase in hybridization intensity at the PF10_0355 
locus compared to the genome average, suggesting that this gene is amplified in some 
parasites (Figure 5B). The amplified region appears only to contain the PF10_0355 gene 
itself and not surrounding loci.  We observed a similar pattern at pfmdr1 on chromosome 
5, where copy number variation is well established (Figure S11). Follow-up qPCR 
analysis of 38 parasite lines confirmed that parasites with amplified PF10_0355 have a 
greater mean halofantrine IC50. (Figure 5C, Table S6, Dataset S1). Copy number 
variation was further confirmed in a number of parasites by quantitative Southern blotting 
(Figure S12).  
Discussion 
In this study we used natural selection and genome-wide association methods to probe 
the genetic basis of adaptation in P. falciparum. These approaches are complementary: 
scanning for selected loci permits an unbiased search for unknown adaptive changes, but 
provides little information about the processes at work, while GWAS gives a focused 
look at one easily identified (and clinically critical) adaptive phenotype. Results from   13 
both approaches open up new avenues for study, as we seek to understand the biological 
significance of the findings.  
The specifics of our strategy were designed to cope with two potential limitations in 
applying genome-wide population genetic approaches to malaria: small sample sizes, due 
to the difficulty in adapting parasites to culture and assessing drug and other phenotypes; 
and a lack of correlation (LD) between nearby variants in the parasite genome, which 
limits our ability to infer untyped SNPs from genotyped markers. The second limitation 
we addressed by developing a high-density genotyping array (based on new sequencing), 
to increase the fraction of genetic variation that we could directly interrogate, while the 
effect of the first was mitigated by the phenotype we targeted in our GWAS. 
Drug resistance is a phenotype well-suited for GWAS because it is expected to be caused 
by common alleles of large effect at few genomic loci [27].  If this is the case, 
associations will be much easier to detect than in a typical human GWAS, in which the 
phenotype is caused by alleles at many loci that are either rare or of small effect. 
Additionally, the haploid nature of the intra-erythrocytic stage of P. falciparum further 
heightens GWAS power by eliminating the issue of allelic dominance. Finally, the 
increased LD caused by recent selection for drug resistance counteracts the loss of power 
that comes from short LD, small sample size, and the temporal and geographic 
stratification of the parasite population that we examined. Thus, despite the potential 
limitations, we were able to detect a known drug resistance locus (pfcrt), observed little 
P-value inflation in our GWAS data (Figures S8-S10), and identified a number of   14 
genome-wide significant loci associated with drug resistance. Part of this success was 
likely due to specific tests we used to account for population structure.  
Going beyond these statistical tests, we went on to functionally validate one of these loci, 
demonstrating that increased PF10_0355 copy number confer resistance to three 
structurally related antimalarial drugs. This demonstrates the feasibility of coupling 
GWAS and functional testing in the malaria parasite for identifying and validating novel 
drug resistance loci and illustrates the power of GWAS to find functionally important 
alleles. 
Comparing our results to the recent GWAS described by Mu, et al. [11], which was also 
directed at finding drug-resistance loci, we see that, beyond the well-known pfcrt locus, 
there was no overlap between the associations identified by each study.  Differing sets of 
drugs tested and analytical methods explain much of the disagreement. Of the eleven 
candidate associations in Table 1, one (that with pfcrt) was found by both studies, eight 
were associations with drugs not assayed in Mu, et al. (atovaquone and halofantrine), and 
two were found only with a haplotype-based test, an approach not used by Mu, et al. Our 
candidate locus at PF10_0355, in fact, would not have been detectable in the Mu study 
because it was identified only by the multi-marker HLR test, because it involved an 
association with halofantrine, and because the Mu, et al. genotyping array lacked markers 
within 4 kb of the gene (plasmoDB.org). 
Different parasite populations and marker sets probably explain many of the 
dihydroartemisinin, mefloquine and quinine associations identified by Mu, et al. but not   15 
seen in our data set. The studies used different parasite population sets—theirs was 
weighted toward southeast Asian strains, and ours toward African strains—and selection 
pressures and selected alleles can both vary between populations. Our smaller sample 
size also means that we might lack power to identify some associations accessible to Mu, 
et al. These difficulties are reflected in human GWAS studies as well, where the ability to 
replicate associations using multiple tests and in different sample sets has also been 
challenging to achieve [28]. 
Ultimately, the disparities in loci identified point to the role of population analysis as a 
tool for candidate gene discovery and not as a definitive study. Even within each study, 
there is little overlap between the signals observed with different methods—our study 
detects only one gene (pfcrt) by both GWAS tests (EMMA and HLR), while Mu, et al. 
detected only two genes (unknowns, not pfcrt) by both of their GWAS tests (Eigensoft 
and PLINK). Even a well-designed GWAS serves only as a hypothesis-generating 
experiment, and it is vital to empirically validate candidate loci associated with a 
phenotype of interest.  Especially given the small sample sizes and relatively sparse 
marker density used in both malaria GWAS studies to date, functional validation of 
candidates is necessary to address concerns about false positive results.  
Our functional result, that increased PF10_0355 copy number confers decreased 
susceptibility to halofantrine, mefloquine and lumefantrine, raises additional questions 
for study.  Further work will be needed to determine the precise contributions of copy 
number variation and gene mutation to the parasite’s response to these drugs. The 
biological function of this gene’s product is unknown, but previous work indicates   16 
putative localization to the parasite surface [29], as well as it being a potential target of 
host immunity and balancing selection [30]. While the protein itself does not appear to be 
a transporter, it is possible that it directly binds drug or perhaps couples with transport 
proteins to modulate drug susceptibility; interaction between membrane transporters and 
non-channel proteins has been demonstrated in cancer, plant and yeast systems [31-33].   
Additional experiments are certainly required to determine the precise role of PF10_0355 
in modulating parasite response to this class of compounds, including assessing its 
relevance to resistance in natural populations, but it is clear that alteration of this locus 
can mediate drug resistance in P. falciparum.  
Although halofantrine, mefloquine and lumefantrine are not commonly used as primary 
interventions, widespread halofantrine use has recently been documented in West Africa. 
Notably, halofantrine was used to treat nearly 18 million patients between 1988 and 2005 
[34,35], and it remains in production and use today. Use of halofantrine, mefloquine or 
lumefantrine as monotherapy may further explain how mutations and copy number 
variation in the PF10_0355 gene were selected. Lumefantrine is also currently used as a 
partner drug in the artemisinin-based combination therapy (ACT) Coartem.  The shorter 
half-life of artemether allows lumefantrine to be present as monotherapy, making it 
vulnerable to selection of drug resistant mutants.  As genetic loci associated with drug 
responses are identified and validated, these provide new molecular biomarkers to 
evaluate drug use and response in malaria endemic settings.  Thus, our findings have 
implications for defining molecular biomarkers for monitoring partner drug responses as 
intervention strategies, such as ACTs, are applied.   17 
Beyond identifying a novel drug resistance locus, this study illustrates the general utility 
of a GWAS approach for the discovery of gene function in P. falciparum. Even with a 
small and geographically heterogeneous sample of parasites, we identified a number of 
new loci associated with drug response and validated one of them. Larger samples from a 
single population will have much greater power to detect additional loci, including those 
where multiple and low frequency alleles contribute to resistance. Future GWAS have the 
potential both to provide greater insights into basic parasite biology and to identify 
biomarkers for drug resistance and other clinically relevant phenotypes like acquired 
protection, pathogenesis, and placental malaria.  
 
Future GWAS will be able to counteract the loss of power caused by low LD, either by 
focusing on parasite populations with reduced outcrossing rates, or by studying cases of 
very strong selective pressure. This issue will soon become moot, however, as the 
declining cost of whole-genome sequencing makes it practical to assay every nucleotide 
in the genome on a routine basis. Culture-adapted parasites are amenable to robust and 
reproducible phenotypic characterization, but their limitations—the potential for 
artifactual mutations during adaptation and for a biased selection of clones within a given 
infection—mean that genetic changes identified using them require both functional 
validation and demonstration that the changes are important during natural infection.  As 
direct sequencing of clinical isolates with demonstrable clinical phenotypes such as ex 
vivo drug response or invasion properties becomes increasingly feasible, sequencing will 
enable us to directly identify genetic changes in the parasite associated with clinically 
relevant phenotypes.  In the years ahead, genome analysis of P. falciparum has the   18 
potential to identify genetic loci associated with many phenotypes, enhance our 
understanding of the biology of this important human pathogen, and inform the 
development of diagnostic and surveillance tools for malaria eradication.   19 
Methods 
Parasites, Drug Testing, and DNA Isolation 
Parasite samples and origins are detailed in Text S1 and Table S1.  Parasites were 
maintained by standard methods [36] and were tested for their response to amodiaquine, 
artemether, artesunate, artemisinin, atovaquone, chloroquine, dihydroartemisinin, 
halofuginone, halofantrine, lumefantrine, mefloquine, piperaquine and quinine according 
to the methods outlined by Baniecki, et al. [37] (Table S4, Figure S13, Text S1). Follow-
up drug testing was done by measuring uptake of 
3H-hypoxanthine [38].  Nucleic acids 
were obtained from parasite cultures using Qiagen genomic-tips (Qiagen, USA). All 
DNA samples were evaluated by molecular barcode [39]. 
Array Genotyping 
We sequenced nine geographically diverse parasite isolates to 1.25x coverage, nearly 
doubling the number of publicly available SNPs to 111,536 (Text S1). These parasites 
had been previously sequenced to 0.25x coverage [2] and the deeper sequencing allowed 
for more thorough SNP discovery.  Using this combined marker set, we created a high-
density Affymetrix-based SNP array for P. falciparum containing 74,656 markers.  
Arrays were hybridized to 57 independent parasite samples (Table S1), including 17 
previously sequenced strains used as a validation set.  Genotype calls were produced 
using the BRLMM-P algorithm [40].  Markers that did not demonstrate perfect 
concordance between sequence and array data for the 17 strains were removed (Text S1).  
The remaining 17,582 SNPs constituted the high-confidence marker set used throughout 
this study (median marker spacing 444 bp, mean spacing 1,316 bp). All genomic 
positions and translation consequences are listed with respect to the PlasmoDB 5.0 
assembly and annotation.  SNP genotype data are publicly available on plasmodb.org 
(release 6.0, July 2009) and dbSNP (Build B134, May 2011), accessible by searching for 
submission batches Pf_0002 (sequencing of nine isolates) and Pf_0003 (genotyping of 57 
isolates) from submitter BROAD-GENOMEBIO.  Genotype data is also available as 
Dataset S2. 
Principal Component Analyses 
Principal components analysis (PCA) was performed using the program SmartPCA [41]. 
All single-infection samples were used for the analysis in Figure 1. Samples that tightly 
clustered with the wrong continental population (A4, Malayan Camp and T2_C6) 
represented likely cases of contamination and were thus omitted from all other analyses. 
Diversity/Divergence Analysis 
We measured diversity using a statistic we term ‘SNP π,’ which quantifies the average 
number of pair-wise differences among samples from a given population at assayed   20 
SNPs. Population divergence was measured using FST, calculated using the method of 
Hudson, et al. [42]. Statistical evaluation of the significance of differences in SNP π and 
FST among populations was performed using a bootstrapping approach, where the SNP 
set was re-sampled with replacement and each statistic recomputed 1000 times. 
Linkage Disequilibrium (LD) Analysis 
The statistic r
2 was calculated within each population for all pairs of SNPs sharing the 
same chromosome [43]; pairs were binned by distance and averaged within each bin. The 
level of LD between unlinked markers was estimated by calculating r
2 between all pairs 
of SNPs on different chromosomes. To determine the bias caused by small sample size, 
the unlinked calculation was repeated, with the change that for each pair of SNPs, the 
genotype for one was taken from one strain while the genotype for the second was taken 
from another strain. This background value of r
2 was calculated separately for the 
possible pairs of different strains and then averaged. Only single infections, as assessed 
by molecular barcode, were used. 
Long Range Haplotype (LRH) Analysis 
Because of the small number of samples, LRH results for individual continental 
populations had a high level of variance. Thus, we pooled together samples from Africa 
(n = 26) and Asia (n = 18, excluding India), as suggested by our PCA analysis. SNPs 
included in the analysis had a minor allele frequency of at least 0.05 and a call rate of at 
least 0.8; missing genotypes were imputed using PHASE.  LRH analysis was performed 
using Sweep.  Each SNP defined two core alleles, one base pair in length.  We calculated 
relative extended haplotype homozygosity (REHH) for each core allele, to its left and 
right [44], yielding up to four REHH scores per SNP locus. We standardized the REHH 
scores as a function of core allele frequency, defined on a discrete grid from 0.05 to 0.95 
with even spaces of 0.025. This yielded a normally-distributed set of Z-scores for which 
we calculated corresponding P-values and Q-values. 
Genome Wide Association Study (GWAS) 
We performed a GWAS for drug resistance to thirteen antimalarials across 50 of our 
genotyped samples. 7,437 SNPs that had a minor allele count of five samples as well as 
an 80% call rate under every phenotype condition were used for GWAS.  A Bonferroni 
significance threshold of –log10(P-value) > 5.17 was used for all tests.  See Text S1 for 
more details on GWAS methods. 
 
The Efficient Mixed-Model Association (EMMA) test [15] models quantitative trait 
associations to a data set with complex population structure and hidden relatedness.  It 
calculates a genotype similarity matrix instead of discrete categories and does not require 
a priori specification of populations.  The resulting P-value distributions demonstrate 
little remaining effect from population structure (Figure S8) while retaining power to find 
a number of associations at genome-wide significance (Figures S8, 2A, Table 1). 
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The Haplotype Likelihood Ratio (HLR) test [16] models the likelihood that a single, 
resistant haplotype rose to dominance while all other haplotypes proportionally 
decreased.  PLINK [45] is used to produce sliding window haplotypes across the genome 
and calculate haplotype frequencies for input to the HLR test.  We produced input for all 
2-, 4- and 6-marker windows. The LOD scores generated by the HLR test were converted 
to empirical pointwise P-values by performing approximately 370,000 permutations of 
the null model for each test condition, allowing us to calculate empirical P-values up to a 
significance of 10
-5.6.  We preserved population-specific phenotype frequencies by 
permuting only within each of three populations defined by our PCA analysis (Table S1).  
Resulting P-value distributions fit expectations well for the vast majority of test 
conditions (Figures S9, S10) and the test demonstrates power to detect a number of loci at 
genome-wide significance (Figure 2A, Table 1). 
Copy Number Variation (CNV) 
Copy number was assessed by evaluating the hybridization intensity at the PF10_0355 
locus on the high-density SNP array (Text S1). Follow-up analyses were done by 
quantitative real-time PCR (qPCR) of the PF10_0355 locus using the Delta Delta Ct 
method [46]. PF10_0355 was compared to the reference locus PF07_0076 and 3D7 was 
used as a reference strain. A summary of PF10_0355 copy number for all parasite strains 
tested is provided in Table S6. Select resistant strains that were found to have multiple 
copies of PF10_0355 were further analyzed by quantitative Southern blotting and 
PF10_0355 copy number was compared to the dhps gene from the 3D7 strain [47]. 
PF10_0355 Overexpression 
The full length ORF of PF10_0355 was amplified from either the Dd2 (HFN sensitive) or 
SenP08.04 (HFN resistant) parasite isolate and cloned into the pBIC009 plasmid under 
the expression of the Hsp86 promoter. Plasmid DNA was isolated, tranfected into the 
Dd2 parasite strain and stable transfectants were selected with 2.5nM WR99210 [48]. 
Parasites from two independent experiments for each vector type (Dd2+Dd2 and 
Dd2+SenP08.04) were isolated and successful transfection was confirmed by plasmid 
rescue as well as episome-specific PCR and sequencing. Additionally, a vector control 
strain was made by transfecting Dd2 parasites with the pBIC009 plasmid containing the 
firefly luciferase gene (EC 1.13.12.7). 
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Table  1.  Eleven  genome-wide  significant  associations  with  antimalarial  drug 
resistance. Positions are given with respect to the PlasmoDB 5.0 reference assembly of 
3D7.  Drug abbreviations are ATV: atovaquone; CQ: chloroquine; HFN: halofantrine; 
ADQ: amodiaquine; ARTS: artemisinin.  The HLR test for CQ-pfcrt association is just 
below the genome-wide significance threshold and is omitted here, but is shown in Figure 
2C. 
 
 
chr  SNPs  test  drug  P-value  genes  PlasmoDB description 
6  674,154  EMMA  ATV  2.36E-07  PFF0785w  Ndc80 homologue, putative 
7  459,787  EMMA  CQ  4.72E-07  MAL7P1_27  chloroquine resistance transporter 
10 
1,435,226, 
1,435,286, 
1,435,370, 
1,437,695, 
1,437,718, 
1,441,590, 
1,444,868 
HLR_risk_6 
(2 overlapping hits)  HFN 
4.71E-06, 
4.25E-06 
PF10_0355, 
PF10_0356 
erythrocyte membrane protein putative, 
liver stage antigen 1 
11  657,349  EMMA  ATV  4.01E-06  PF11_0178  conserved unknown 
11  738,407  EMMA  HFN  7.20E-07  PF11_0203  peptidase, putative 
11 
1,123,028, 
1,124,030  HLR_risk_2  ADQ  5.26E-06  PF11_0302  conserved unknown 
12  1,964,935  EMMA  HFN  6.15E-08  PFL2285c  conserved unknown 
13  757,689  EMMA  HFN  1.28E-07  PF13_0101  conserved unknown 
14  1,233,470  EMMA  HFN  5.32E-07  PF14_0293  conserved unknown 
14 
2,814,793, 
2,815,714  HLR_risk_2  ARTS  4.90E-06  PF14_0654  aminophospholipid transporter, putative 
14  3,130,449  EMMA  ATV  1.03E-06  PF14_0729  early transcribed membrane protein 14.2   28 
Figure 1. Parasite global population structure and genetic diversity vs. divergence. 
(A) Population structure is visualized using the first two principal components of genetic 
variation  for  57  parasites.  Solid  circles  represent  individual  parasites,  with  colors 
assigned by reported origin: Africa in red, America in blue, and Asia in green.  The nine 
strains used for ascertainment sequencing are indicated with (*). (B) Genetic diversity 
(SNP π) in Senegal versus divergence (FST) between Senegal and Thailand is reported for 
688 genes containing >3 successfully genotyped SNPs. Blue diamonds: enzymes, acyl-
CoA synthetases (ACS) or transporters; red diamonds: antigens, vars, rifins, stevors or 
surfins; gray diamonds: all other genes. Gene IDs (PlasmoDB.org) for highlighted genes 
are listed in Table S7. A gene with unknown function is flagged with (*) to indicate that 
SNP π is off-scale (0.014). 
 
Figure  2.  Genome-wide  association  study  (GWAS)  results.  (A)  Genome-wide 
significant associations were found for five antimalarials (out of thirteen tested) using 
EMMA and HLR tests. They include pfcrt (chromosome 7) associated with chloroquine 
resistance and eleven novel associations with resistance to several drugs, listed in Table 
1. (B) Quantile-quantile plots for the P-value distributions in (A) show no significant 
confounding from population structure.  Bonferroni-corrected genome-wide significance 
is marked with a dashed line; Benjamini-Hochberg significance is marked with a dotted 
line.  (C-D) Close-ups are shown of the GWAS signal (top) and haplotypes (bottom) for 
resistance to (C) chloroquine (CQ) around the gene pfcrt and (D) halofantrine (HFN) 
around the gene PF10_0355. Yellow: sensitive allele; red: resistant allele; Blue: no data. 
Isolates are ordered by IC50, with the highest IC50 on the bottom. 
 
Figure  3.  Overexpression  of  PF10_0355  decreases  parasite  susceptibility  to 
halofantrine  (HFN)  and  related  antimalarials.  Parasite  susceptibility  to  six 
antimalarials was measured by 
3H-hypoxanthine incorporation. Comparisons were made 
between Dd2 (HFN-sensitive strain) and SenP08.04 (HFN-resistant strain), as well as 4 
transfected  lines.  “Dd2+Dd2”:  Dd2  parasites  overexpressing  PF10_0355  from  Dd2; 
“Dd2+P08”: Dd2 parasites overexpressing PF10_0355 from SenP08.04. Overexpression 
of PF10_0355 decreases parasite susceptibility to (A) HFN and structurally related (B) 
mefloquine (MFQ) and (C) lumefantrine (LUM). Overexpression of PF10_0355 does not 
alter  parasite  susceptibility  to  (D)  chloroquine  (CQ),  (E)  artemisinin  (ARTS)  or  (F) 
atovaquone (ATV). Mean IC50 ± standard error is shown. Significance levels: *: p<0.05, 
**: p<0.01, ***: p<0.001. 
 
Figure  4.  Correlations  between  antimalarial  drugs  tested.  (A)  Pearson  correlation 
values (r) between log10(IC50) values are rendered as a color in a symmetric correlation 
matrix  (red:  correlated;  white-uncorrelated,  blue:  inversely  correlated).  Thirteen 
antimalarials  are  measured:  artemether  (ARTM),  artesunate  (ARTN),  artemisinin 
(ARTS),  dihydroartemisinin  (DHA),  halofantrine  (HFN),  lumefantrine  (LUM), 
mefloquine (MFQ), quinine (QN), chloroquine (CQ), amodiaquine (ADQ), atovaquone 
(ATV),  piperaquine  (PIP),  and  halofuginone  (HFG).  Drugs  are  grouped  by  structural 
relatedness.  (B-F)  Correlation  plots  are  given  with  a  linear  regression  line  for  HFN 
compared  to  the  5  other  drugs  tested  for  antimalarial  resistance  with  PF10_0355 
overexpression: (B) LUM, (C) MFQ, (D) ATV, (E) CQ, and (F) ARTS.   29 
 
Figure 5. Copy number variation at PF10_0355 is associated with HFN resistance. 
(A). Mean PF10_0355 copy number (± standard deviation for three replicates) in the 
parent  Dd2  and  transfected  lines  from  qPCR  analysis.  Dd2+Dd2:  Dd2  parasites 
overexpressing  PF10_0355  from  HFN-sensitive  Dd2;  Dd2+P08:  Dd2  parasites 
overexpressing PF10_0355 from HFN-resistant SenP08.04. Copy number was compared 
to the reference locus PF07_0076. (B) Increased hybridization intensity at PF10_0355 on 
the  high-density  SNP  array,  measured  by  Z-scores  for  normalized  and  background-
corrected data, for the HFN-resistant isolate SenP19.04. (C) Strains with increased copy 
number of PF10_0355 (as measured by qPCR > 1.2x 3D7) show a significantly higher 
resistance to HFN (p = 0.02, Student t-test). 0 
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